|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 295 GBX | 0.00% |
|
-6.35% | -16.31% |
| Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
| Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
MaxCyte, Inc. announced the signing of a strategic platform license (SPL) to support the development of Be Bio's BCMs programs. Under the terms of the agreement, Be Bio obtains non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation®? technology and ExPERT?? platform.
In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.31% | 384M | |
| +8.59% | 219B | |
| +6.66% | 183B | |
| +10.45% | 133B | |
| +24.41% | 108B | |
| +0.27% | 63.06B | |
| +12.17% | 52.02B | |
| +3.96% | 48.2B | |
| +0.06% | 40.37B | |
| +13.93% | 39.35B |
MAXCYTE, INC. 
